Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-10
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Good morning, and thank you for joining Guggenheim's Third Annual Healthcare Innovations Conference. I'm Devjit, and my privilege to host George McGrath and Rob Gagnon from Opus Genetics. George is the CEO and Rob, the CFO. Thank you both for making time for us.
Yeah, thank you.
So it's been a really interesting year for you guys, especially I think you've cracked the harder nut with the best data. So maybe let's start there. So before we get to the best stuff, let's quickly get an overview of the pipeline, and then we can, you know, spend time on the best and the initial data.
Yeah, absolutely. So, you know, Opus has a pipeline of gene therapies mostly out of the University of Pennsylvania from Gene Bennett that are all gene augmentation using known vectors going after different types of inherited retinal degenerations that potentially show improvement of vision. So what you'll see in our data set is we like to always try to show improvement of function, not just preservation of vision. And we have our most advanced program. It's called LC5. It is by far 10x, our smallest indication, but it's right in the middle of a pivotal trial. That trial will read out next year with potential BLA filing next year if the data holds. And then BEST-1 is a really interesting story. It's our next pipeline program that we'll talk about in some detail, but much larger indication at 23,000 or so patients. We have proof-of-concept data and a low-dose early cohort with an additional cohort coming in Q1. And we also are about to be dosing patients in two additional mutations, one called RDH12, which is about 10 times the size of a luxterna, like it's 2,500 or so patients. MRTK is about the same epidemiology. Both of those are more visual cycle type programs that we're excited to be treating patients in now.
Got it. And so the BIRD1 clinical data that were reported earlier this year, obviously from the low-dose cohort, I think it surprised people not just with the data, but the fact that you had alignment with the FDA when you put out the data. So it took, you know, the guessing game was off.
Yes.
Right. So can you sort of talk to that data set? Because I think initially there was the expectation of the subretinal fluid, but then you had something much more remarkable than just the subretinal fluid.
Yeah, yeah. So BES-foteliform macular dystrophy is really characterized by the presence of the teleform material. And the teleform material is lipofusen or byproducts of the visual cycle and working photoreceptors that is not transported into the circulatory system for disposal in patients who are missing the best tropin channel. And so fundamentally, the holy grail for this disease is to replace the best tropin channel and remove the vitelloforum material. And that's exactly what we showed in at least two of our BVMD patients in cohort one. Interestingly enough, like the coolest part they said for me is that retinal sensitivity in exactly those same areas dramatically improved. And so the vitelloforum material is really a marker of where you have rescuable photoreceptors, and those photoreceptors, when you do rescue them by removing the ptel4 material, the sensitivity improves quite dramatically. If we had just taken those loci where the ptel4 material was, we would have seen about a four and a half or so decibel improvement on microperimetry, and as you guys know from the literature, three decibels is the improvement is equivalent of 15 letters on an eye chart. It's a really dramatic improvement in function of the retina. Now, the subretinal fluid, we initially, these patients in cohort one were in-stage patients with kind of a lake of subretinal fluid with the teleform material around the periphery of it. And the subretinal fluid did not change, and I think that's a characteristic of the fact that there is very little viable photoreceptors in that subretinal fluid. I think that's kind of like a central graveyard for the retina. And that was really elucidated by an Italian study that was published in early September where they showed the natural history of 13 patients over five years. And what they showed was in the area of central fluid, it doesn't really change. Like everything just kind of stays the same. But each year, the area where the teleformed material is, they call it a transitional zone, that area decreases on average by a half a decibel. No patient got better. They all decreased. And the fluid would just kind of circumferentially get bigger each year. And so I think that the telephone material is kind of just where the action is in these patients. What we're going to see in cohort two is much more early stage patients. And so it's going to be a little bit different because of that than what we saw in cohort one and for that reason. Pretty excited.
And it's also a higher dose cohort.
And it's a higher, it's about three times the dose. Yeah. So it's a much higher dose. Yeah.
Yeah. I mean, that's the interesting thing about when you think about the pipeline, you've sort of, you can go after loss of function mutations, which maybe is easier not to crack. But then to sort of address dominant negative mutations like you did with. Yes. Best. That, that, that's where the skepticism was. Yes. On paper it should work, but we didn't know how much you needed to go up before. Before you saw the effect.
Yes.
And you hit it with the first dose. So, yes, obviously expectations now for the second dose are higher. I don't know if that's a good thing or a bad thing, but
yeah, I mean, and what I would say about that is like, it's, it's a great point, right? So I do think fundamentally the September readout, that was what it was about was, is it going to work and be in best for teleform macular dystrophy, which is the dominant version. And I think we showed at least in those first few patients that it does, or it's very promising that it might. Now, the magnitude of effect that we saw in that first dose was quite high. And so I think that the idea that a higher dose will cause a marginal improvement over that. It is a tall bar for the drug product because we're already at a really good place from cohort one, so I don't know if we're going to see, I mean, what I would love to see is just consistency, right? If we can show 11 more patients, 10 of which are BVMD, if we can just show consistent results in line with low variability compared to what we saw, you know, in line with what we saw in cohort one, we'll be like really, I think we'll be really de-risked going into this time.
Is there a way to identify patients who are more likely to respond?
Yes, yes. Based on the data we have to date, it's all about the presence of the Vitell4 material. So we want patients that have active Vitell4 material and Vitell4 material in regions that we can treat with the gene therapy and that is unconfounded with additional pathology, like the lack of subrandial fibrosis, things like that.
So any registration study, you do plan to enrich for these patients, and hence, probability once you move into phase three should be relatively high.
I think that's the key. That, to me, that's what I'm most interested in in cohort two, is my ability to use the data from cohort two to increase the prior probability of success in phase three.
Got it. Ange, you want to have?
Sure. Maybe, you know, going to pivotal trial and the alignment with the FDA about the endpoint, I think you have seven pre-specified endpoints that should show statistical significance in improvement. Maybe can you just talk us through how you choose those points?
Yep, yep. The easiest way to choose the points is just look at the white, at the hyper-autofluorescence spots on the autofluorescent image. So the autofluorescence image is a high-resolution image of the retina, and lipofusen is bright white. So what you see on our patients. 101-106 is the most clear example of this we have public so far. There's these little white balls on that image. If you were to just pick the loci specifically over those white balls, you would have had four and a half decibel improvement at three months. So it's quite meaningful. It's a good question because you want to be not only sensitive, but also specific on this, right? Because you're taking an arithmetic average of the spots you choose. So you don't want to have false, you don't want to have patients, you don't want to have spots that don't move, right? Um, so, so really it's a, it's a, the key, the key in my mind is not only the sensitivity, but also the specificity. So I want to pick the spots that are most likely to improve. And so, so we're actually doing a lot of work in the background right now on characterizing the lesions, like actually characterizing the teleformed lesions to see if you can put a predictive value on those spots based on the dimensions of those lesions. And so there is There's more to come on that. Like, right now... What we know is that we would meet the bar if we just simply picked the spot, but we do think there's room to improve by what you said. Which spots do you pick? Do you pick them all? Are there certain ones that may not move? Are there certain ones that are more likely to move?
Can you talk about the vitiliform material? This gets deposited in the early stages of the disease and maybe gets reabsorbed as the disease progresses.
Yeah, yeah, it does. So the vitiliform material is actually lipofusen, which is a byproduct of the visual cycle that gets deposited, that basically gets produced by the photoreceptors and transported into the coroidal circulatory system for disposal by the best tropon channel. So when the best tropin channel is missing, that vitiliform material backs up. It's like the garbage truck didn't come, right? It's like you get a big mound of this stuff. So early in disease, you actually get this big yellow lesion. They call it an egg yolk. And those patients have very little subrinal fluid, if any, almost none. It's just a vitiliform material. And that vitiliform material puts a metabolic stress on the photoreceptors, which causes the sensitivity of the photoreceptors to light to start to go down. Now, as you get later in the disease process, that egg yolk starts to scramble, right? So the vitelloform material starts to break up, and then you end up with subretinal fluid, and the vitelloform material starts to go away. The reason for that is because the photoreceptors are atrophying over it. So as the photoreceptors atrophy, they're producing less vitelloform material, and so that vitelloform material that is there starts to kind of break up and go away, And you're left with an area just of subretinal fluid. And so in cohort one, all of our patients are sort of that stage four or five, where you get, where you have like that fluid with minimal vitelloform lesion around the edges. In cohort two, you'll actually see majority of stage three, coupler stage four. You'll see at least one Stage 2. So, the demographics are fundamentally shifting towards earlier stage patients in cohort two.
So, when you think about the registration study, then, do you want to enroll across the spectrum or with an eye on the label, or how should we think about that?
I think that you want to, I think the most predictable response is going to be in the earlier stage patients. We have a lot to learn on that in cohort two. But based on cohort One, that is what we've seen. And so I think from a standpoint of increasing the prior probability of success, the phase three, I think the more homogeneous early-stage population you get, the better. Now, from a labeling standpoint, it'll be interesting to see. We haven't had those discussions yet, but I would expect the label would be for patients with the best disease And that we wouldn't be... We wouldn't be pigeonholed into an early stage population because we have shown really meaningful functional improvement for patients at end stage, including like a 63-year-old who could see on the eye chart for the first time since she was 15 years old. So I think that it would be, you know, we'll see. We'll have those discussions. It would be a travesty if you couldn't offer it to later stage patients because we've seen a really important improvement in those patients' quality of life.
Got it. And on the alignment with the FDA, the greater than three decibel change in microparametry, that's like a patient reported. So, outcome, right?
Yeah.
So, how do you sort of, or how do we understand this patient-reported outcome? Because in other disease, forget retinal disease, in other diseases, it's usually been a stumbling block.
Yeah, yeah, yep, yep, yep. So, the way micropermetry is done is the patient is looking into sort of a bowl, and they have a clicker, and when they see a light, they click the button. And so what the machine does is it actually shines light on different places of the retina, and then it'll shine at multiple times, and it'll vary the intensity to give you, you know, basically a luminance that they can see out of, and that's what the decibel is. And so, it is a patient-reported outcome. It is a subjective outcome, but it's a little bit more objective than a lot of things because there is a stimulus followed by a reply from the patient. What we've seen in natural history is that normal fluctuation is about a half a decibel. Three decibels is way outside of normal variability. Thank you. And we've also seen specifically in BEST disease, in BVMD, the dominant BEST disease, that there's a kind of uniform decrease over time by about a half a decibel a year. And so that'll be the primary endpoint. Now, there is another PRO component to it where it's a responder analysis between two groups. To be a responder, you have to hit microperimetry that we talked about. You also have to hit the PGIS, which is Patient Global Impression of Severity, which is a scale, ordinal scale. It's a question, a very simple question. Rate the severity of your disease, and then, you know, say zero to five, something like that. And so that was, that's how the primary endpoint is set up, is a responder analysis where the responder, It has an improvement on both.
And you have to sort of pre-select seven spots. Right. So how do you guarantee fidelity while you select those seven spots?
Pre-specify. It doesn't have to be seven. It has to be at least five. It can be up to as many as you want. You do have to pre-select them before the surgery happens. And so what we likely will do, and we're working out this methodology with cohort two, but what we likely will do is just have a little committee of key opinion leaders to get together before the patient is operated to pick the loci that we'll include for that patient.
Go ahead. Andrzej, you want to have?
Maybe just how would that approach then translate into real world when you can't have these KRL committees? Mm-hmm.
So in the real world, micropermetry is really a tool of clinical trial, mostly. In the real world, I think... I think that these patients will be treated without a requirement of microperimetry improving. I think that what the physicians in the real world will be more interested in is the sort of activities of daily living improvements, which in our cohort one have been quite dramatic.
Can you talk to the prevalence and diagnosis rates? You know, how challenging is it to diagnose? And, you know, at some point you have to probably start preparing for a commercial launch.
Yeah, maybe I'll let Rob talk about the epidemiology and his commercial launch. Yeah, yeah.
So originally we thought the prevalence was 8400, and that was based off of the documented databases out there for best disease. We were hearing from various KOLs that they thought the number was quite higher, and George can talk about what that's like in practice. We actually commissioned a third party to go out there and do some work to help validate that. And they went out to 150 eye specialists, really a bottoms-up approach, quantitative approach, came back with a result of about 23,600 patients in the U.S. Do you want to talk about the egg yolk lesion?
So the reason we did that was because BEST1 is unique for IRDs. So most IRDs, when you look at the retina, they look the same, right? It's hard, you know, to diagnose Stargardt, you need to have a Stargardt, you need to have an ABCA4 genetic test. To diagnose BEST disease, you don't have to have that because the egg yolk lesion can be diagnostic, can be pathognomonic. And so for a majority of physicians out there, when they see an egg yolk lesion, when they see a best disease patient, they tell the patient they have best disease. There's nothing you can do about it, and they don't get referred to a tertiary care center or genetically tested. So when we were reporting 8400, we thought that we were doing that from basically the published literature that's out there that typically gets genetic databases and tertiary care centers. The KOLs were out there telling everybody in the world that we were way off. They were like, for every Stargardt patient I see, I see a best patient. It's like, I'm all in the order of that. And it was like one KOL call where they flat out asked him in a public call, like, why does the company say A400? He's like, I don't know, they're wrong. So, Rob and the team, Rob and a guy named Joe Shackle on our team commissioned a more quantitative approach that he described that came out to be... I got a lot of I told you so's from the KOLs when we showed them the results.
It came out to be what they were saying it was. And then on commercial launch, we're starting to think about that now. And it's going to be a very targeted approach. It's going to leverage digital technologies as much as possible. But probably looking at FTEs somewhere in the range of 20 to 30 in total. So it'll be very fit to purpose for the launch and for the size of the market opportunity. Right.
And you think the pivotal study of the registration study gets underway back end of next year? Mm-hmm. Data holds, yeah. How quickly can you enroll and sort of is this a 29, back-end 29 kind of approval?
Yeah, so the company hadn't officially guided on that, but yeah, I think that math kind of, like, I think that would be logical. The enrollment, I mean, look, 11 patients from mid-August, and they were all done and treated by October, so pretty fast, like, when it starts going, and there was a lot more demand than the 11 patients, too, so the patients were, like, there's... I think this thing could potentially go quickly.
So let's talk about the remainder of the pipeline, especially with the focus on 2027 now.
Well... You want to start with LCA5 and how that's meaningful to us?
Yeah, LCA5, well, we think there's approximately 200 patients, maybe just under 200 patients, but a lot of them are captured at Penn, so we know who they are now. But LCA5 will also come with a voucher, so that's something that we'll be working towards to initiate the auction process that would probably fall in the 2028 timeline. Likely, I think I've seen some of those go off recently at 200, 205, even maybe 225. 215 was the highest. 215, yeah. So we'll be working towards that in 2028. It'll be a great source of capital. Fund, really, the rest of the pipeline for us. But we have a number of other exciting programs, too. We're making good progress with RDH12 and TK.
So, RDH12 is probably the most eminent one, so we'll be dosing patients like any day now on that one. That one is probably the most straightforward read-through to Lecloxterna. RDH12 is visual cycle, LCA, that we should see an improvement. I mean, what we'd be looking for is FST within a few months moving. So that'll be sort of the guidepost for whether or not we're getting target engagement on that program. Mur-TK is an exciting one, too. Lots of... Lots of patients, for RDH12 and MIRTK, lots of patients in the Middle East where they actually get comparable pricing for Luxtern as the U.S., but on the order of like $15,000 to $20,000 in the MENA region. So MIRTK is actually being sponsored in Abu Dhabi by the Department of Health there. That one is kicking off as we speak as well. I mean, kicking off as in treating patients imminently. That one is an exciting one, too. There's a lot of experience in MIRTK. It's a well-characterized disease. I think both, certainly RDH12, I think both of them have a pretty high probability of success from a technical standpoint. So both of those will read out some data. Either next year or early 28. So, essentially, you have four data readouts next year, the Pivotal LCA, the best one, RDH-12, and RTK.
And Rob, where are you with your, you know, ability to fund everything? I mean, clearly, there's this stuff here. It's a PRV machine, but...
There's a lot. I think that really speaks to the business model, because we estimate from an IND to a BLA, it takes us about three years and costs us about $30 million, so it's a very efficient business model. We put out our update Q3 earnings release this morning. We'll be filing a 10Q later today. Our cash as of September 30th was about $90 million. And we actually had some warrant exercises. We also have a milestone coming in this quarter from Phantolamine, that legacy asset that was licensed, essentially a financial asset for us at this point. The long and short of it is pro forma. We have about 100 million of cash sitting here today. We have a runway into 2029. And the reason for that is we have an additional 70 million of available capacity on our credit facility. So a good long runway. We can work the math so that the voucher in 2028 could be the next financing for the company. We'll just have to see.
Well, congrats on all the progress. I'm looking forward to the next data updates next year.
Yeah. Thanks, Devjit.
Thank you.
Appreciate the time.
0:02 to 24:07 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Good morning, and thank you for joining Guggenheim's Third Annual Healthcare Innovations Conference. I'm Devjit, and my privilege to host George McGrath and Rob Gagnon from Opus Genetics. George is the CEO and Rob, the CFO. Thank you both for making time for us.
George Magrath: Yeah, thank you.
Sure. Maybe, you know, going to pivotal trial and the alignment with the FDA about the endpoint, I think you have seven pre-specified endpoints that should show statistical significance in improvement. Maybe can you just talk us through how you choose those points?
George Magrath: Yep, yep. The easiest way to choose the points is just look at the white, at the hyper-autofluorescence spots on the autofluorescent image. So the autofluorescence image is a high-resolution image of the retina, and lipofusen is bright white. So what you see…
Can you talk about the vitiliform material? This gets deposited in the early stages of the disease and maybe gets reabsorbed as the disease progresses.
George Magrath: Yeah, yeah, it does. So the vitiliform material is actually lipofusen, which is a byproduct of the visual cycle that gets deposited, that basically gets produced by the photoreceptors and transported into the coroidal circulatory system for disposal by the…
Maybe just how would that approach then translate into real world when you can't have these KRL committees? Mm-hmm.
George Magrath: So in the real world, micropermetry is really a tool of clinical trial, mostly. In the real world, I think... I think that these patients will be treated without a requirement of microperimetry improving. I think that what the physicians in the real world will…
Can you talk to the prevalence and diagnosis rates? You know, how challenging is it to diagnose? And, you know, at some point you have to probably start preparing for a commercial launch.
George Magrath: Yeah, maybe I'll let Rob talk about the epidemiology and his commercial launch. Yeah, yeah.
Also speaking: Robert Gagnon